A new 'In Discussion With' episode featuring Sehar Shahid on the pace of weight loss with GLP-1 receptor agonists. Few details shared beyond the topic.
Recap by typeshit. Post by Facebook on Facebook.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
The student says the gray-market blend worsened his anxiety. MOTS-c discoverer Pinchas Cohen says samples sold online held little or none of the peptide.
Two people familiar with the plan say the FDA would hold back enforcement on certain popular peptides, even though its own scientists said none were studied enough.
Loading…